China approves Pfizer GLP-1 drug for weight management  Reuters

Priovant, a company backed by Pfizer, has received FDA priority review for its lead asset, indicating a fast-tracked evaluation process for a new drug.

Novavax has projected a 2026 revenue target of $230 million to $270 million, supported by a new partnership with Pfizer and a cost reduction strategy.

Pfizer announced that its drug Braftovi has received full approval from the FDA for the treatment of colorectal cancer.

Pfizer in diabetes drug deal with Sciwind Biosciences  Reuters

Pfizer Inc (PFE) has announced positive results from its BREAKWATER trial, marking a significant development for the pharmaceutical company.

A New Jersey woman is among over 2,000 individuals suing Pfizer, alleging complications from a birth control product she believed was safe.

Pfizer has received approval in China for its obesity drug, positioning itself in the market as generic alternatives are anticipated.

An investor shares a reason why they would happily buy Pfizer (PFE) stock and never sell, offering a long-term bullish perspective.

RBC Capital initiates coverage on Pfizer (PFE) with a $25 target, highlighting structural revenue headwinds.

An analysis suggests that Pfizer, a dividend giant, could provide significant income for healthcare allocations.

An analysis explores whether Pfizer stock is an underrated investment opportunity within the healthcare sector.

Analysts are providing their outlook on where Pfizer Inc. (PFE) is headed, offering insights into its future performance.

Argus adopts a bullish stance on Pfizer, emphasizing the company's GLP-1 and oncology pipeline developments.

Pfizer Inc. and Astellas Pharma have announced positive results from their Phase 3 EV-304 clinical trial for the drug PADCEVTM.

An analysis evaluates whether Pfizer's stock is underperforming compared to the broader healthcare sector.

Pfizer has finalized a deal worth $495 million to secure the rights for an obesity drug in China, expanding its pharmaceutical presence in the region.

Moderna is facing a lawsuit alleging that its COVID-19 vaccine violates a patent linked to the Pfizer/BioNTech shot.